Italy is a leading pharmaceutical producer in Europe: yet the country has seen few innovative products discovered and trialed locally.
Most investments are directed towards the later stages of the drug supply chain, focusing on product improvement, administration, and packaging.
What can be done to change this situation?
The newly established National Center for mRNA and Gene Therapies, launched last December at the University of Padua, will allow us to take an important step in the right direction.
Takis proudly joins this innovative hub, comprised of 16 pharmaceutical companies and 32 research institutes.
The consortium aspires to become a focal point in European research for precision medicine. Its primary goal is to conduct cutting-edge research, establish robust infrastructures, and foster collaborative innovation to develop personalized therapies.
At Takis, we are eager to contribute our expertise in target selection, nucleic acid manufacturing, vaccination in predictive models, and the generation of in vivo CAR-T cells.
We strongly believe that public-private collaboration can lead to revolutionary solutions for future vaccines and therapies.
